Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
October 15 2018 - 8:00AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that new data from studies of its lead antifungal
rezafungin will be presented at the 2018 Hot Topics in Infectious
Diseases (HTIDE) Conference to be held in Mestre, Venice from
October 25-26, 2018. Rezafungin is the only once-weekly antifungal
product candidate in development for the treatment and prevention
of life-threatening invasive fungal infections.
A total of three rezafungin abstracts have been accepted for
poster presentations. Two posters will highlight analyses of
rezafungin in special patient populations and by geographic
outcomes based on results from Cidara’s Phase 2 STRIVE trial. The
third poster will highlight the in vivo efficacy of rezafungin in
aspergillosis.
Hot Topics in Infectious Diseases (HTIDE) is a bi-annual
conference which convenes more than 400 delegates from all over the
world to discuss topics on novel approaches to diagnosis and
treatment of infectious diseases. Cidara’s HTIDE posters will be on
display throughout the conference and featured in a poster walk
discussion during the lunch session on both days. Details are as
follows:
Title: Rezafungin for the Treatment of Candidemia and/or
Invasive Candidiasis: Analysis of the Global, Randomized,
Double-Blind, Placebo-Controlled Phase 2 STRIVE Clinical Trial by
Geographic Region of EnrollmentAuthor: T. Sandison, et. al.
Title: Analysis of Patients by Baseline Renal Function from the
Phase 2 STRIVE Clinical Trial of Rezafungin for the Treatment of
Candidemia and/or Invasive CandidiasisAuthor: S. Flanagan, et.
al.
Title: Of Mice and Men: Comparison of Rezafungin versus
Micafungin Lung Exposures in Mouse, and Potential Implications for
Human ELF and Efficacy StudiesAuthor: V. Ong, et. al.
Copies of these presentations will be available on the Cidara
website following the meeting: www.cidara.com.
About Rezafungin
Rezafungin is a novel antifungal echinocandin being developed as
a once-weekly, high-exposure therapy for the treatment and
prevention of serious invasive fungal infections. Rezafungin has a
unique pharmacokinetic profile with a prolonged half-life and
front-loaded plasma exposure which, in contrast to all other
echinocandins, allows for once-weekly IV therapy. Rezafungin is
being studied to address unmet needs in the treatment of candidemia
and invasive candidiasis as well as for prophylaxis (prevention) of
invasive fungal infections, including Candida, Aspergillus and
Pneumocystis in patients undergoing allogeneic bone marrow
transplantation.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, in a Phase 3 clinical trial in the treatment of
candidemia and invasive candidiasis and plans to initiate a second
Phase 3 trial in the prophylaxis of invasive fungal infections.
Rezafungin has improved pharmacokinetics compared to existing
echinocandins and the potential for expanded utility across patient
settings. It is the only once-weekly product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections. Cidara also is leveraging its novel
Cloudbreak™ platform to develop antibody-drug conjugates for the
treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and
also direct a patient’s immune cells to attack and eliminate
bacterial, fungal or viral pathogens. Cidara is headquartered in
San Diego, California. For more information, please visit
www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the initiation of rezafungin Phase 3 pivotal trials, the potential
for rezafungin to be a novel treatment and prophylactic agent
against deadly invasive fungal infections, and rezafungin’s
potential for expanded utility across patient settings. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop
and commercialize its product candidates; Cidara’s ability to
obtain additional financing; Cidara’s ability to obtain and
maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel.
These and other risks and uncertainties are described more fully in
Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Cidara undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181015005259/en/
INVESTORS:Westwicke Partners, LLCRobert H. Uhl,
858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIA:Sam Brown
Inc.Christy Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From May 2023 to May 2024